Literature DB >> 3556104

Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients.

T Agner, P Damm, C Binder.   

Abstract

To elucidate beta-cell function, insulin requirement, and remission period in insulin-dependent diabetes mellitus (IDDM), a study was undertaken comprising 268 patients consecutively admitted to Steno Memorial Hospital with newly diagnosed IDDM. The patients were characterized by sex, age, and seasonal variation at onset of diabetes mellitus. During the first 36 mo of the disease, an evaluation was performed for basal C-peptide, HbA1c, and insulin dose per kilogram. Total remission was interpreted as complete discontinuation of insulin therapy for at least 1 wk while still metabolically well controlled, and partial remission was interpreted as an insulin need that was less than or equal to 50% of the insulin dose at discharge from the hospital. During the first 18 mo of the disease, 12.3% of the patients entered total remission (median 6 mo), and 18.3% of the patients entered partial remission (median 6 mo). Patients entering remission had significantly higher basal C-peptide levels than those who did not. Sex, age, and initial HbA1c levels did not influence the frequency of remission.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556104     DOI: 10.2337/diacare.10.2.164

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  12 in total

1.  Changes in GAD65Ab-specific antiidiotypic antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity.

Authors:  E Ortqvist; B Brooks-Worrell; K Lynch; J Radtke; L M Bekris; I Kockum; C-D Agardh; C M Cilio; A L Lethagen; B Persson; A Lernmark; J Reichow; S Oak; J P Palmer; C S Hampe
Journal:  J Clin Endocrinol Metab       Date:  2010-08-04       Impact factor: 5.958

2.  Long-term risk of IDDM in first-degree relatives of patients with IDDM.

Authors:  T Lorenzen; F Pociot; P Hougaard; J Nerup
Journal:  Diabetologia       Date:  1994-03       Impact factor: 10.122

3.  Partial remission phase of diabetes in children younger than age 10 years.

Authors:  B J Muhammad; P G Swift; N T Raymond; J L Botha
Journal:  Arch Dis Child       Date:  1999-04       Impact factor: 3.791

4.  Biometry of the crystalline lens in late onset diabetes: the importance of diabetic type.

Authors:  J M Sparrow; A J Bron; N A Phelps Brown; H A Neil
Journal:  Br J Ophthalmol       Date:  1992-07       Impact factor: 4.638

5.  Dynamic changes in CD4+ CD25+(high) T cell apoptosis after the diagnosis of type 1 diabetes.

Authors:  S Glisic-Milosavljevic; T Wang; M Koppen; J Kramer; S Ehlenbach; J Waukau; P Jailwala; S Jana; R Alemzadeh; S Ghosh
Journal:  Clin Exp Immunol       Date:  2007-08-17       Impact factor: 4.330

Review 6.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

7.  Fasting plasma C-peptide, glucagon stimulated plasma C-peptide, and urinary C-peptide in relation to clinical type of diabetes.

Authors:  H J Gjessing; L E Matzen; O K Faber; A Frøland
Journal:  Diabetologia       Date:  1989-05       Impact factor: 10.122

8.  Nocturnal electroencephalogram registrations in type 1 (insulin-dependent) diabetic patients with hypoglycaemia.

Authors:  I Bendtson; J Gade; A M Rosenfalck; C E Thomsen; G Wildschiødtz; C Binder
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

9.  Proinsulin and C-peptide at onset and during 12 months cyclosporin treatment of type 1 (insulin-dependent) diabetes mellitus.

Authors:  O Snorgaard; S G Hartling; C Binder
Journal:  Diabetologia       Date:  1990-01       Impact factor: 10.122

10.  Altered CD161 bright CD8+ mucosal associated invariant T (MAIT)-like cell dynamics and increased differentiation states among juvenile type 1 diabetics.

Authors:  Robert Z Harms; Kristina M Lorenzo; Kevin P Corley; Monina S Cabrera; Nora E Sarvetnick
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.